Payment overview · 2025
General Payments
$2,160.50
101 reported records · 16 companies
Healthcare provider profile · identity verified
Jon Trister, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WORCESTER, MA · NPI 1639131352
Verified facts
What the public records show
CMS Open Payments records show Jon Trister, M.D. received $2,160.50 in general payments during 2025 across 101 reported records.
ABBVIE INC. accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 313 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 313 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $384.51 | 17.8% | 14 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $326.89 | 15.1% | 14 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $200.19 | 9.3% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $188.18 | 8.7% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $175.43 | 8.1% | 8 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $165.95 | 7.7% | 7 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $154.23 | 7.1% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $144.70 | 6.7% | 7 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $104.28 | 4.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $80.40 | 3.7% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $79.16 | 3.7% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $62.51 | 2.9% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.75 | 1.3% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $24.28 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.86 | 1.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.18 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,160.50 | 101 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $326.89 | 14 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $214.65 | 8 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $177.45 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $169.86 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $165.95 | 7 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $154.23 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $132.54 | 6 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $104.28 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $87.93 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $81.38 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $80.40 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $79.16 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $62.51 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.05 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.05 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.91 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.91 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 193 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 313 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
313 | 70 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
313 | 70 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
193 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 731 | 221 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 583 | 168 |
| Omeprazole | Omeprazole | 504 | 157 |
| Losartan Potassium | Losartan Potassium | 483 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 449 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 441 | 126 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 438 | 130 |
| Metformin Hcl | Metformin Hcl | 378 | 114 |
| Lisinopril | Lisinopril | 352 | 108 |
| Jardiance | Empagliflozin | 313 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 309 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 296 | 92 |
| Gabapentin | Gabapentin | 286 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 244 | 76 |
| Furosemide | Furosemide | 222 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 215 | 62 |
| Ezetimibe | Ezetimibe | 203 | 59 |
| Alprazolam | Alprazolam | 197 | 36 |
| Eliquis | Apixaban | 193 | 44 |
| Atenolol | Atenolol | 192 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 179 | 67 |
| Zolpidem Tartrate | Zolpidem Tartrate | 146 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 141 | 39 |
| Trazodone Hcl | Trazodone Hcl | 138 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 44 |
| Prednisone | Prednisone | 132 | 31 |
| Ibuprofen | Ibuprofen | 131 | 49 |
| Sertraline Hcl | Sertraline Hcl | 131 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 42 |
| Carvedilol | Carvedilol | 122 | 29 |
| Lorazepam | Lorazepam | 122 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 120 | 31 |
| Finasteride | Finasteride | 119 | 41 |
| Simvastatin | Simvastatin | 110 | 40 |
| Allopurinol | Allopurinol | 109 | 27 |
| Potassium Chloride | Potassium Chloride | 108 | 34 |
| Chlorthalidone | Chlorthalidone | 98 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 98 | 55 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 97 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 95 | 22 |
| Celecoxib | Celecoxib | 89 | 28 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 86 | 41 |
| Spironolactone | Spironolactone | 77 | 23 |
| Clonazepam | Clonazepam | 76 | 17 |
| Glipizide | Glipizide | 72 | 22 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 62 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 23 |
| Azithromycin | Azithromycin | 59 | 49 |
| Ketoconazole | Ketoconazole | 59 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 21 |
| Famotidine | Famotidine | 58 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 56 | 18 |
| Creon | Lipase/Protease/Amylase | 55 | 14 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 55 | 16 |
| Meclizine Hcl | Meclizine Hcl | 53 | 26 |
| Metformin Hcl Er | Metformin Hcl | 53 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 26 |
| Diazepam | Diazepam | 50 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 50 | 16 |
| Sucralfate | Sucralfate | 50 | 12 |
| Lidocaine | Lidocaine | 49 | 12 |
| Torsemide | Torsemide | 49 | 20 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 46 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 13 |
| Ammonium Lactate | Ammonium Lactate | 45 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Hydrocortisone | Hydrocortisone | 41 | 18 |
| Linzess | Linaclotide | 41 | 17 |
| Valsartan | Valsartan | 41 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 35 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Nystatin | Nystatin | 29 | 13 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | 12 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 14 |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | 11 |
| Olanzapine | Olanzapine | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Codeine Sulfate | Codeine Sulfate | 26 | suppressed |
| Methadone Hcl | Methadone Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Metronidazole | Metronidazole | 25 | 12 |
| Clotrimazole | Clotrimazole | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Triazolam | Triazolam | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Zolmitriptan | Zolmitriptan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,160.50 · 101 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, BREZTRI, COMIRNATY, ELIQUIS, FREESTYLE LIBRE 3, FUROSCIX, GEMTESA, IBSRELA, JARDIANCE, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, UBRELVY, VOQUEZNA, VOWST, VRAYLAR, XIFAXAN, ZENPEP, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error